At Lonza we always welcome interest and inquiries from the media about our business, services and capabilities. Please use the resources on this page, or contact our media relations team for specific inquiries, and we will connect you to the appropriate business leader or subject matter expert.

27 January 2021
Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and...
Lonza delivers on guidance1 with CHF 4.5 billion sales, 12.0%2 sales growth, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% marginLonza...
19 January 2021
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage...
Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology...
18 January 2021
Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment...
Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for...